MEK inhibitors have been proven to be effective in cancers with constitutive activation of the MAPK/ERK pathway and have been investigated in UM, which displays GNAQ/GNA11-mutations in >90% of cases [17,18]. The gene discussed is GNAQ; the disease is cancer.